Ignite Creation Date:
2024-05-06 @ 8:21 PM
Last Modification Date:
2024-10-26 @ 3:26 PM
Study NCT ID:
NCT06351813
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-10
First Post:
2024-03-25
Brief Title:
Predicting Adverse Kidney Events of Cardiac Surgery-Associated Acute Kidney Injury Using Novel Biomarkers
Sponsor:
Shanghai Zhongshan Hospital
Organization:
Shanghai Zhongshan Hospital
Study Overview
Official Title:
Predicting Adverse Kidney Events of Cardiac Surgery-Associated Acute Kidney Injury Using Novel Biomarkers--A Multicenter Observational Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study was to identify and validate novel biomarkers for predict acute kidney injury AKI subphenotype major adverse kidney events and other poor outcomes
Detailed Description:
Cardiac surgery-associated acute kidney injury CSA-AKI is a serious condition that is associated with increased mortality and morbidity However the current criteria for assessing the severity of AKI may not adequately capture the heterogeneity of this condition This can lead to difficulties in identifying treatment effects in specific patient subgroups which may contribute to the growing number of negative interventional trials in AKI To address this issue researchers have developed and validated two subphenotypes of AKI resolving and nonresolving These subphenotypes are based on the trajectory of serum creatinine SCr levels in the first 3 days after hospital presentation By stratifying AKI patients based on these subphenotypes we can better assess their risk and predict outcomes
Several novel biomarkers have been developed to aid in the early detection of AKI discrimination of its underlying causes and prediction of outcomes However it remains unclear whether these biomarkers can accurately predict the development of a nonresolving AKI subphenotype In our present study we aim to address this gap in knowledge by conducting a large cohort study Our goal is to identify and validate novel biomarkers that can effectively detect the resolving subphenotype of AKI as well as predict major adverse kidney events and other poor outcomes
Several novel biomarkers have been developed to aid in the early detection of AKI discrimination of its underlying causes and prediction of outcomes However it remains unclear whether these biomarkers can accurately predict the development of a nonresolving AKI subphenotype In our present study we aim to address this gap in knowledge by conducting a large cohort study Our goal is to identify and validate novel biomarkers that can effectively detect the resolving subphenotype of AKI as well as predict major adverse kidney events and other poor outcomes
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None